← Russell 3000 cross-section

ELAN Elanco Animal Health Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$12.4bn
Revenue TTM
$5.0bn
Net income TTM
$-199m
Free cash flow
$379m
Composite score
Sector rank
#625

Valuation

P / E
EV / EBITDA
EV / sales
3.1
FCF yield
3.05%
Earnings yield vs 10-yr
-6.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4.0%
EBITDA margin
ROE
-3.0%
ROIC
Revenue growth
11.9%

Insider activity, last 90 days

Net open-market
$1.47m
Buyers
5
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Product Development and Regulatory Update A key element of our targeted value creation strategy is to drive revenue growth through portfolio development and product innovation. Expected pre-tax charges associated with the 2025 Restructuring Plan total $25 million to $30 million in 2026, of which $17 million was incurred during the six months ended June 30, 2026, primarily related to the remaining shut-down costs for our Monheim, Germany, facility. Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. …Elanco Animal Health Inc, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →